In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial / Garcia-Manero G.; Almeida A.; Fenaux P.; Gattermann N.; Giagounidis A.; Goldberg S.L.; Ozawa K.; Weaver J.; Santini V.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - STAMPA. - 19:(2019), pp. 213-219. [10.1016/j.clml.2018.12.012]
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
Santini V.
2019
Abstract
In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2152265018315209-main_Lenalidomide.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
694.12 kB
Formato
Adobe PDF
|
694.12 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
